Stockreport

Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility [Seeking Alpha]

Agios Pharmaceuticals, Inc.  (AGIO) 
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.agios.com/investor-overview
PDF Mitapivat met the primary hemoglobin endpoint but failed to significantly reduce pain crises or improve fatigue, casting doubt on its real-world efficacy. AGIO plans [Read more]